Researchers have discovered and analyzed a rare but serious side effect of an innovative form of blood cancer therapy. The ...

Emerging reports show that metabolic pathways can be targeted to enhance T cell-mediated immunity to tumors. Yet, tumors consume key metabolites in the host to survive, thus robbing T cells of these ...

A patient has achieved over 18 years of remission from neuroblastoma, a type of nerve cell cancer, following treatment with ...

1Laboratory of Synthetic Immunology, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy.

ω-6) PUFAs significantly delays tumor progression, decreases M2 polarization, and increases M1 polarization and infiltration of CD4+ T cells. M2 macrophages from tumors in mice fed a high ω-3 diet ...

“The way we traditionally grow T cells in the lab is horribly inefficient,” explained senior author Dr. Greg Delgoffe, professor in the Department of Immunology at Pitt’s School of Medicine and ...

Tumour immunology ... tumor cells leads to the recruitment of immunosuppressive PMN-MDSCs to tumors, thereby impairing anti-tumor immunity and diminishing the effectiveness of immunotherapies. CD8 ...

T-knife Therapeutics, Inc., a biopharmaceutical company developing T cell receptor (TCR) engineered T cell therapies (TCR-T) ...

T-knife was founded by leading T cell and immunology experts utilizing technology developed at the Max Delbrück Center for ...

Various immune cells are involved in both innate and acquired immunity against tumors. NK cells and cytotoxic T lymphocytes play ... kinase inhibitors in tumor immunology by summarizing their ...

Researchers have discovered and analysed a rare but serious side effect of an innovative form of blood cancer therapy. The scientists from the University of Leipzig Medical Center, the Fraunhofer ...